Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

New tool can identify patients at high risk of venous thromboembolism

A new risk prediction tool can identify patients at high risk of serious blood clots (known as venous thromboembolism) who might need preventative treatment, says a study published on bmj.com today.

17 Aug 2011

Survey: 35% of people in the UK fear cancer more than other life-threatening conditions

More than a third of people in the UK fear cancer more than other life-threatening conditions - such as Alzheimer's, stroke and heart disease according to a Cancer Research UK survey.

16 Aug 2011

NanoString to begin clinical development program for Breast Cancer Intrinsic Subtyping Assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay.

From NanoString Technologies 4 Aug 2011

Taxoxifen combined with dasatinib reverses chemo-resistance in breast cancer cells

Taking a leukemia chemotherapy drug may help breast cancer patients who don't respond to tamoxifen overcome resistance to the widely-used drug, new research from the Kimmel Cancer Center at Jefferson suggests.

2 Aug 2011

Scientists show how RET gene in breast cancer cells responds to estrogen

Using human breast cancer cells and the protein that causes fireflies to glow, a Johns Hopkins team has shed light on why some breast cancer cells become resistant to the anticancer effects of the drug tamoxifen. The key is a discovery of two genetic "dimmer switches" that apparently control how a breast cancer gene responds to the female hormone estrogen.

28 Jul 2011

Medco announces new offerings within Advanced Oncology Solutions

Medco Health Solutions, Inc. today announced new offerings within its Advanced Oncology Solutions, that include treatment pathways decision support with embedded pharmacogenomic testing and nutrition recommendations for cancer patients.

20 Jul 2011

Cancer rates increase among middle-aged people in Great Britain

CANCER rates in middle-aged men and women in Great Britain have gone up by nearly 20 per cent in a generation - an increase of 17,000 cases a year - according to new figures released today (Monday) by Cancer Research UK.

18 Jul 2011

Treatment with estrogen dramatically lowers rates of stomach cancer in male mice

Several types of cancer, including stomach, liver and colon, are far more common in men than in women. Some scientists have theorized that differences in lifestyle, such as diet and smoking, may account for the discrepancy, but growing evidence suggests that the differences are rooted in basic biological differences between men and women.

14 Jul 2011

Conventional Estrogen Receptor measurement methods may result in 10-20% false negative rate

A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.

28 Jun 2011

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.

27 Jun 2011

APP to commence marketing Letrozole Tablets for breast cancer in the U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited.

7 Jun 2011

Exemestane reduces risk of breast cancer in high-risk, postmenopausal women

Today's major announcement at the American Society of Clinical Oncology annual meeting that the drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role.

6 Jun 2011

Starving breast cancer cells of hedgehog significantly slows tumour growth and spread

While it is already known that breast cancer cells create the conditions for their own survival by communicating their needs to the healthy cells that surround them, Australian researchers have identified a new way of turning off that cellular cross talk.

4 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Many women over 70 with stage I breast cancer opt for radiation therapy: ASCO

Patterns of radiation usage in breast conserving therapy for women 70 years and older with stage I breast cancer are changing: more women are opting for radioactive implants and those with estrogen positive tumors are opting out of radiation therapy, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4.

3 Jun 2011

Tamoxifen News and Research

Further Reading

New tool can identify patients at high risk of venous thromboembolism

Survey: 35% of people in the UK fear cancer more than other life-threatening conditions

NanoString to begin clinical development program for Breast Cancer Intrinsic Subtyping Assay

Taxoxifen combined with dasatinib reverses chemo-resistance in breast cancer cells

Scientists show how RET gene in breast cancer cells responds to estrogen

Medco announces new offerings within Advanced Oncology Solutions

Cancer rates increase among middle-aged people in Great Britain

Treatment with estrogen dramatically lowers rates of stomach cancer in male mice

Conventional Estrogen Receptor measurement methods may result in 10-20% false negative rate

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

APP to commence marketing Letrozole Tablets for breast cancer in the U.S.

Exemestane reduces risk of breast cancer in high-risk, postmenopausal women

Starving breast cancer cells of hedgehog significantly slows tumour growth and spread

Researcher to evaluate new approach for treatment of triple-negative breast cancer

Many women over 70 with stage I breast cancer opt for radiation therapy: ASCO

Positive preliminary results from Genomic Health's Oncotype DX study in DCIS breast cancer

Scientists find new drug target in breast cancer

Researchers identify new drug resistant protein in breast cancer

New breast cancer biomarker may help identify women's response to tamoxifen

Estradiol may exacerbate tumor growth in breast cancer

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News